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Abstract
Pulmonary hypertension (PH) is classified into five groups based on disease etiology but there is only limited information on the
prognostic value of exercise testing in non-group 1 PH. In group 1 PH, the incremental shuttle walking test (ISWT) distance has
been shown to correlate with pulmonary hemodynamics and predict survival without a ceiling effect. This study assessed the ISWT
in non-group 1 PH. Data were retrieved from the ASPIRE Registry (Assessing the Spectrum of Pulmonary hypertension Identified
at a REferral centre) for consecutive patients diagnosed with PH. Patients were required to have been systematically assessed as
group 2–5 PH and to have a baseline ISWTwithin three months of cardiac catheterization. Patients were stratified according to
incremental shuttle walk test distance (ISWD) and ISWT distance percent predicted (ISWD%pred). A total of 479 patients with
non-group 1 PH were identified. ISWD and ISWD%pred correlated significantly with symptoms and hemodynamic severity. ISWD
and ISWD%pred predicted survival with no ceiling effect. The test was prognostic in groups 2, 3, and 4. ISWD and ISWD%pred and
change in ISWD and ISWD%pred at one year were all significant predictors of outcome. In patients with non-group 1 PH the ISWT
is a simple non-invasive test that is easy to perform, is predictive of survival at baseline and follow-up, reflects change, and can be
used in the assessment of PH of any etiology.
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Introduction
Many mechanisms can lead to an elevation of resting mean
pulmonary arterial pressure (mPAP). Pulmonary hyperten-
sion (PH) is classified into five groups according to distinct
pathophysiological characteristics.1 Group 1 (pulmonary
arterial hypertension [PAH]) has been the most studied
but PH due to other causes is more common.2,3
Whatever the cause, PH places a substantial burden on
the patient, contributing to the severity of disease and
affecting quality of life.4–9 As exercise limitation is a sig-
nificant symptom in PH, it is important that exercise tests
used for the assessment of physical functioning reflect the
severity of disease. Currently, two exercise tests are mainly
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used in patients with PAH: the 6-min walking test
(6MWT), which is an unencouraged field test; and the car-
diopulmonary exercise test (CPET), which is an incremen-
tal maximal test.
Because of its simplicity, the 6MWT is the test most fre-
quently used to monitor patients in the clinic and assess the
efficacy of new therapies. However, concerns have been
raised regarding the use of the 6MWT.10–13 In milder dis-
ease, a ‘‘ceiling effect’’ has been noted where 6-min walking
distance (6MWD) no longer reflects maximal oxygen aer-
obic capacity (VO2peak)
14–16 or disease severity;17 the test
has been shown to be unresponsive to clinically important
changes in hemodynamic parameters,17–20 while change in
6MWD does not explain a large proportion of observed
treatment effect.21–23 Very few studies look specifically at
the prognostic significance of the 6MWT distance in non-
group 1 patients.24–26
CPET is a more complex test. It provides information on
the etiology of exercise limitation,27 provides prognostic
information,28 reflects hemodynamic severity and, unlike
the 6MWT, reflects VO2 peak even in mild disease.
However, due to its complexity, routine use of CPET is
challenging and when used in a randomized controlled
trial, it was unable to demonstrate a treatment effect.29 In
addition, the prognostic utility of CPET variables may also
differ according to the etiology of PAH.30
The ISWT is an externally paced symptom-limited test
requiring the patient to walk around a 10 -m course. The
speed increases every minute and patients continue walking
until they can no longer keep pace with the signal. Strong
correlations are found between distance walked and VO2
peak in patients with different diseases, including heart fail-
ure.31,32 In addition to correlating more strongly than the
6MWT with VO2 peak, the ISWT has been found to be a
better predictor of survival than the 6MWT in chronic heart
failure.33
The ISWT shares benefits of both the 6MWT and CPET.
It is simple and quick to perform but also has the benefits of
an incremental nature to maximum exercise capacity. In
addition, as the test uses a 10 -m course rather than the
30 -m corridor required for the 6MWT, it is easy to perform
in the clinical environment. Because of these advantages, the
ISWT has been proposed as an alternative field walking test
to the 6MWT in PAH,34,35 and a small study looking spe-
cifically at patients with PAH noted that ISWT distance
(ISWD) correlated more closely with peak oxygen consump-
tion than 6MWT distance.36
Using data from the ASPIRE Registry, we recently
demonstrated in patients with PAH that distance walked
during the ISWT correlated with pulmonary hemo-
dynamics, World Health Organization (WHO) functional
class (FC) and resting Borg score, and predicted prognosis
both at baseline and at subsequent follow-up, all without a
ceiling effect.37 This study now assesses the usefulness of the
ISWT in patients with non-group 1 PH.
Methods
Data were retrieved from the ASPIRE Registry for consecu-
tive patients diagnosed with PH, defined as having a
mPAP 25mmHg, during 2001–2010, as previously
described.38
For inclusion, patients were required to have been system-
atically assessed as group 2–5 PH (PH due to: left heart dis-
ease¼ group 2; lung disease and/or hypoxemia¼ group 3;
chronic thromboembolic PH [CTEPH]¼ group 4; and
unclear or multifactorial etiologies¼ group 5) and to have a
baseline ISWT within three months of cardiac catheteriza-
tion. Patients with multiple potential causes of PH were
excluded to allow comparisons between single phenotypes,
e.g. patients with connective disease with left heart disease or
lung disease or patients with CTEPH and significant co-exist-
ing left heart disease or lung disease, were excluded (Fig. 1).
Ethical approval was granted by the North Sheffield
Research Ethics Committee (reference no. 06/Q2308/8).
Incremental shuttle walk test
The ISWT was performed according to the method of Singh
et al.39 Using a standardized recording, patients were asked
to walk as far as possible around the 10-m course keeping in
time to the audio signal until they were too breathless or
could no longer keep up with the speed. The initial walking
speed was 0.50m/s and this increased incrementally every
minute to a maximum of 2.37m/s. The primary measure
Fig. 1. The study cohort.
PH, pulmonary hypertension; ISWT, incremental shuttle walk test;
CTD, connective tissue disease; PAH, pulmonary arterial hypertension.
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was distance walked. In addition, breathlessness was mea-
sured at rest before the ISWT and at the end of the test.
Percent predicted ISWT distance (ISWT%pred) was calcu-
lated for each patient based on sex, age, and body mass
index using the equation derived by Probst et al.40
Patients were recorded as walking 0m if they could not
complete 1 shuttle length in the required time while breath-
ing room air. A small proportion of patients who were on
high flow O2 who were unable to remove their oxygen and
attempt to walk along the corridor were assigned a walking
distance of 0m, if in the opinion of the physiologist they
were unable to complete 1 shuttle length.
Follow-up
Survival status was ascertained at the census point via the
NHS enhanced reporting service. Data were collected for
patients who had had a repeat assessment at 12 months
(2 months) after diagnosis.
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics
v19 (SPSS, Chicago, IL, USA). Continuous variables were
described by mean standard deviation (SD). If data were
not normally distributed, results were presented as
median interquartile range (IQR). Categorical variables
are presented as n (%). Pearson’s correlation test was used
to assess correlations between ISWD or ISWD%pred and
hemodynamic parameters and was tested for two-sided sig-
nificance. Student’s t-test and Mann–Whitney U test were
used to compare groups. Multiple comparisons between
groups were performed using ANOVA. Event (death or
transplantation)-free survival from date of diagnosis was
estimated using the Kaplan–Meier method with comparison
between groups performed by the log-rank test. The accur-
acy of the prognostic parameters was estimated using recei-
ver operating characteristic (ROC) curves. A P value< 0.05
was deemed statistically significant.
Stratification of patients
A model with five pre-specified bands based on walking dis-
tance/maximal walking speed was used as previously
described for group 1 PAH:37 band 1¼ 0–30m; band
2¼ 40–120m; band 3¼ 130–250m; band 4¼ 260–420m;
and band 5¼ 430–1020m. ISWD%pred was similarly stra-
tified into five bands: band 1¼ 0–10%; band 2> 10–20%;
band 3> 20–35%; band 4> 35–60% and band 5> 60%. At
follow-up, improvement in ISWD was defined as an increase
>40m, decline was defined as a decrease >20m, and the
remaining patients were defined as stable. Improvement in
ISWD%pred was defined as an increase in ISWD%pred of
>10%, decline was defined as a decrease of >4%
ISWD%pred, and the remaining patients were defined as
stable. Patients were also grouped by age to assess the utility
of the ISWT in more elderly patients.
Results
A total of 479 patients with non-group 1 PH were identified
(Fig. 1). Patient characteristics are shown in Table 1. Data
completeness was high (>90%). Median distance walked at
baseline was 120m and median time to complete the walk
was 3.2min. Details of treatment are given in
Supplementary Table S1A.
Disease severity
ISWD and ISWD%pred correlated significantly both with
the severity of symptoms (Borg score and WHO FC) and
with hemodynamic parameters including right atrial pres-
sure (RAP), pulmonary vascular resistance (PVR), cardiac
output, cardiac index, and mixed venous oxygen saturation
(all P< 0.001). mPAP also correlated with ISWD
(P¼ 0.025) and ISWD%pred (<0.001). One-way ANOVA
demonstrated highly significant relationships (P< 0.001)
across all ISWD and ISWD%pred bands with WHO FC,
baseline resting Borg score, and baseline pulmonary hemo-
dynamic parameters (Fig. 2). Analyzing etiological groups
separately, in groups 3 and 4, ISWD and ISWD%pred
correlated significantly with mPAP, mRAP, CI, PVR, and
WHO FC. In addition, in group 4, ISWD and ISWD%pred
also correlated with SmVO2. In group 2, ISWD correlated
significantly with only SmVO2 and WHO FC while
ISWD%pred correlated with mPAP and WHO FC
(Supplementary Table S2).
Baseline ISWD and survival
Kaplan–Meier survival analysis demonstrated that both
baseline ISWD and baseline ISWD%pred predicted survival
with no ceiling effect across the five bands (both P< 0.001)
(Fig. 3). ROC analysis found no significant difference in the
predictive power for long-term survival between ISWD and
ISWD%pred (area under the ROC curve [AUC]¼ 0.693,
95% confidence interval [CI]¼ 0.646–0.739 and 0.703,
95% CI¼ 0.657–0.750, respectively). Analyzing the PH
groups separately, Kaplan–Meier survival analysis demon-
strated that both baseline ISWD and baseline ISWD%pred
predicted survival in groups 2, 3, and 4 (all P< 0.005); ana-
lysis was not performed in group 5 due to small numbers
(n¼ 27) (Fig. 4). In addition to baseline ISWD predicting
long-term outcome in all patients with CTEPH, it also pre-
dicted outcome in patients undergoing (n¼ 94, P¼ 0.045)
and not undergoing surgery (n¼ 108, P¼ 0.008) during
the study period. ISWD%pred also predicted outcome for
all CTEPH patients (P¼ 0.002) and patients not undergoing
surgery (P¼ 0.009) but was not a significant predictor in
those who had had surgery,
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Follow-up
Follow-up data were available for 150 patients at one-year
follow-up. Mean change in ISWD (ISWD) was þ37
128m (P¼ 0.001, paired t-test). Kaplan–Meier analysis
showed that the ISWD at one year and ISWD%pred at
one year were significant predictors of outcome (both
P< 0.001). Sub-analysis of data on CTEPH patients
(n¼ 93, 49 having endarterectomy) showed that patients
ISWD predicted long-term survival (P¼ 0.04).
Age
Of the patients, 57% were aged65 years. Patient character-
istics stratified by age are shown in Table 2. At baseline,
mPAP, CI, and SmvO2 were significantly lower in the older
patients while there was no significant difference in PVR and
mRAP. Those aged 65 years presented with more severe
functional decline, with only 12% being in WHO FC 1 or 2
compared to 24% of patients aged <65 years (P¼ 0.002).
This was reflected by a significantly lower ISWD and lower
ISWD%pred. The distribution of patients in the distance
bands also differed: of the older patients, 9% walked
>250m and 17% walked >35% predicted ISWD compared
with 32% and 26%, respectively, in the younger patients.
Nonetheless, although overall survival in older patients was
worse than in patients aged <65 years (Fig. 5a), ISWD and
ISWD%pred were significant predictors of long-term
survival (Fig. 5b and c) and were as effective predictors of
one-year survival in the elderly (AUC¼ 0.670, 95%
CI¼ 0.557–0.776 and AUC¼ 0.701, 95% CI¼ 0.600–0.802,
respectively) as for the younger patients (AUC¼ 0.678, 95%
CI¼ 0.587–0.770 and AUC¼ 0.707, 95% CI¼ 0.621–0.792,
respectively). Cox multivariate survival analysis, including
either ISWD or ISWD%pred, hemodynamic parameters
mRAP, mPAP, PVR, CI, and SmVO2, age, sex, and WHO
FC I, II versus WHO FC III, IV, showed both ISWD or
ISWD%pred to be independent predictors of outcome in
both age groups. As well as predicting survival in older
patients, ISWD and ISWD%pred also reflected disease
severity in the elderly group, correlating significantly (all
P< 0.005) with mRAP, mPAP, PVR, CI, and SmVO2 and
WHO FC (Supplementary Table S2).
Discussion
This study is the first to show that in non-group 1 PH
patients that distance walked using the ISWT, whether
absolute or expressed as a percentage of predicted walking
distance, correlates with baseline pulmonary hemo-
dynamics, WHO FC, and resting Borg score, and predicts
prognosis both at baseline and at subsequent follow-up.
Furthermore, this test is prognostic of survival when the
data are analyzed as a whole group, in separate etiological
groups and older patients aged 65 years. Follow-up
ISWTT distance had prognostic value, emphasizing the
need for assessment at multiple timepoints.41
Patients with group 2–5 PH represent a substantial per-
centage of the patients referred to specialist PH centres;26,38
however, with the exception of group 4 (CTEPH), little has
been published previously on the predictive significance of
exercise tests in non-group 1 PH. There have been some











Female (n (%)) 240 (50) 69 (67) 51 (35) 105 (52) 15 (56)
Age (years) 65 13 70 10 66 11 61 15 58 15
WHO FC Iþ II/IIIþ IV (%) 17/83 28/72 12/88 15/85 15/85
mRAP (mmHg)* 10.0 (8.0) 14.0 (9.0) 9.0 (6.0) 10.0 (7.0) 11.0 (10.0)
mPAP (mmHg) 43 11 39 13 43 12 47 11* 43 12
PWP (mmHg) 13.8 6.7 23.2 4.3 11.9 5.0 10.6 4.4 10.4 4.2
CI (L/min/m2)* 2.6 (1.1) 2.9 (0.8) 2.8 (1.3) 2.4 (1.0)* 2.8 (1.5)
PVR (Wood Unit)* 5.8 (6.7) 2.7 (2.3) 5.3 (6.0) 8.4 (6.1)* 6.0 (6.8)
SmvO2 (%) 62 9 64 9 65 8 60 8* 59 11
FEV1 (%pred) 69 23 69 21 55 24 79 18 68 25
FVC (%pred) 83 24 78 23 74 27 91 20 81 19
FEV1/FVC (%) 68 13 71 10 60 17 71 12 68 17
Tlco (%pred) 53 21 62 17 34 17 63 16 41 21
ISWT distance (m)* 120 (160) 120 (150) 80 (130) 140 (210) 120 (160)
ISWT time (min)* 3.2 (2.9) 3.2 (2.8) 2.4 (2.6) 3.5 (3.4) 3.2 (2.8)
Values are presented as mean SD for parametric data and *median (IQR) for non-parametric data.
mRAP, mean right atrial pressure; mPAP, mean pulmonary artery pressure; PWP, pulmonary wedge pressure; LHD, left heart disease; CTEPH, chronic thrombo-
embolic pulmonary hypertension; CI, cardiac index; PVR, pulmonary vascular resistance; SmvO2, mixed venous oxygen saturation; FEV1, forced expiratory volume
in 1 s; %pred, % predicted; FVC, forced vital capacity; TLco, transfer factor of the lung for carbon monoxide; ISWT, incremental shuttle walk test.
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Fig. 2. Relationship between baseline ISWT bands. (a) Band 1 ISWD m¼ 10–30; band 2¼ 40–120; band 3¼ 130–250; band 4¼ 260–420; band
5¼ 430–1020; (b) ISWD%predicted band 1¼ 0–10; band 2> 10–20; band 3> 20–35; band 4> 35–60; band 5> 60.
CI, cardiac index; PVR, pulmonary vascular resistance; RAP, right atrial pressure; SmVO2, mixed venous oxygen saturation; %WHO Class 1þ 2,
percentage of patients in World Health Organization functional class I and II (all P< 0.001).
Fig. 3. Kaplan–Meier survival analysis stratified according to baseline. (a) ISWD and (b) ISWD%predicted.
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studies of the predictive significance of the 6MWT in single
non-group 1 PH sub-groups. A study of patients with PH
related to heart failure with preserved ejection fraction
found that 6MWD was an independent predictor of
hospitalization and/or death for cardiac reasons.24 It has
been shown that shown that 6MWD reflected the clinical
and hemodynamic severity of disease in patients with
CTEPH and the change in the 6MWD correlated with the
observed clinical and hemodynamic improvement.26 One
small study looking at the full range of group 2–5 PH
found, in 60 patients, that a 6MWD< 400m was associated
with a higher risk of death. Numbers were too small to
analyze etiological groups separately and follow-up data
were not available.25 Analysis of survival data from the
Giessen Pulmonary Hypertension Registry, the largest
single-center PH registry, found that 6MWD was a pre-
dictor of outcome across all groups of PH, although the
results were most robust in group 1.26 In groups 2, 3, and
4, they found that survival of the top quartile of patients
who walked >390m was not significantly better than
patients in the third quartile who walked 311–390m. Our
study demonstrates the utility of a field exercise test in dif-
ferent PH diagnostic groups and across the range of disease
severity with no ceiling effect.
Currently, guidelines do not recommend any PAH-
specific drugs for the treatment of patients with group
2–5PH, but to consider trials of therapy in carefully selected
patients with severe PH.43Nonetheless, studies have shown a
Fig. 4. Kaplan–Meier survival analysis stratified according to baseline ISWD in patients with PH due to (a) left heart disease, (b) lung disease, and
(c) CTEPH, and stratified by ISWD%predicted in patients with PH due to (d) left heart disease; (e) lung disease, and (f) CTEPH.





Female n (%) 102 (49) 138 (51) >0.05
WHO FC Iþ II n (%) 49 (24) 32 (12) <0.001
mRAP mmHg* 10.0 (9.0) 11.0 (7.0) >0.05
mPAP mmHg 45 12 42 10 0.001
CI L/min/m2* 2.8 (0.8) 2.6 (0.7) 0.002
PVR Wood Unit* 6.0 (6.9) 5.8 (6.7) >0.05
SmvO2 (%) 64 9 62 9 0.019
Wedge mmHg 13 7 14 7 0.029
ISWD* m 180 (203) 80 (130) <0.001
ISWD%pred* 24 (24) 16 (24) <0.001
WHO FC: World Health Organization functional class; mRAP: mean right atrial
pressure; mPAP: mean pulmonary artery pressure: CI: cardiac index; PVR: pul-
monary vascular resistance; SmvO2: mixed venous oxygen saturation; ISWD:
incremental shuttle walk distance
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significant number of these patients do receive PAH-targeted
therapies44,45 and the need to evaluate therapies in groups 2
and 3 has been highlighted.44–47 We have demonstrated that
the ISWT is a useful tool for assessing exercise capacity for
clinical monitoring and may have utility as an endpoint in
trials of targeted therapies for non-group 1 PH.
Limitations of study
The models of prediction using the ISWT were based on
retrospective data from a single specialist PH center.
Although the numbers were high at baseline (n¼ 479) and
allowed analysis of groups 2–4, there were insufficient num-
bers to allow sub-group analysis. In addition, only 150
patients were re-evaluated at one year, limiting follow-up
analysis, since it is not the policy of the center to follow-
up group 2–5 patients unless they are receiving specific inter-
ventions. For patients with CTEPH, surgery is a potential
confounding factor influencing outcome. Nonetheless, at
baseline, ISWT distance predicted outcome for patients
both undergoing and not undergoing surgery.
The data in this Registry were collected when PH was
defined as a mPAP 25mmHg. The definition of PH has
recently been updated to mPAP> 20mmHg.48 Further
work is required to evaluate the utility of the ISWT in
patients with mPAP> 20mmHg and <25mmHg.
In addition, the nature of this study precludes any com-
parison with the current standard field walking test used in
the evaluation of PH (6MWT). However, this study further
highlights the utility of the ISWT in the evaluation of
patients with PH.
Conclusion
The ISWT is a simple non-invasive test that is easy to
perform in patients with non-group 1 PH, is predictive of
survival at baseline and follow-up, and reflects change.
We have demonstrated that the ISWT can be used to predict
outcome in both group 1 and non-group 1 PH.
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